scPharmaceuticals Inc. (SCPH)

Market Cap	168.13M
Revenue (ttm)	30.28M
Net Income (ttm)	-80.12M
Shares Out	50.04M
EPS (ttm)	-1.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	306,943
Open	3.500
Previous Close	3.520
Day's Range	3.270 - 3.500
52-Week Range	3.075 - 6.710
Beta	0.14
Analysts	Strong Buy
Price Target	15.00 (+346.43%)
Earnings Date	Nov 13, 2024

About SCPH

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROS...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 17, 2017
• Employees: 136
• Stock Exchange: NASDAQ
• Ticker Symbol: SCPH
• Website: https://www.scpharmaceuticals.com

Analyst Forecast

According to 2 analysts, the average rating for SCPH stock is "Strong Buy." The 12-month stock price forecast is $15.0, which is an increase of 346.43% from the latest price.

Price Target

$15.0

(346.43% upside)

Analyst Consensus: Strong Buy